NCT00034502已完成1 期
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 10
研究概览
简要总结
This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis of locally or metastatic colorectal cancer
- •Prior therapy with 5-FU for metastatic cancer
- •Adequate bone marrow, liver and kidney function
排除标准
- •Pregnancy
- •Breast feeding
- •Inability to interrupt aspirin therapy
- •Brain metastasis
- •Patients who have been treated previously with ALIMTA or irinotecan
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal CancerColorectal CancerNCT00079872Eli Lilly and Company120
已完成
2 期
Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy FailureLiver MetastasesColorectal CancerNCT01348412Centre Georges Francois Leclerc31
Unknown
1 期
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal CancerColo-rectal CancerNCT03545711Chinese Academy of Medical Sciences42
已完成
3 期
E. Coli Nissle in OncologyGastric CancerColorectal CancerNCT02706184University of Hohenheim20
已完成
1 期
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal CancerColorectal CancerNCT00209625Hokkaido Gastrointestinal Cancer Study Group23